GlassScriptPhysician profile
Martin Sarkar
NPI 1518005636
$1,123,567.39
in general payments reported to CMS, 2019-2025
34 companies · $229K in 2025
The $229K reported for 2025 was more than what 99% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $175K · 2020: $142K · 2021: $112K · 2022: $189K · 2023: $122K · 2024: $155K · 2025: $229K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $287K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $121K · Travel and Lodging: $51K · Food and Beverage: $19K · Consulting Fee: $16K · Honoraria: $13K · Education: $87.52 · Gift: $59.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $286,536.13 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $121,014.00 |
| Travel and Lodging | $50,569.66 |
| Food and Beverage | $18,924.40 |
| Consulting Fee | $15,868.00 |
| Honoraria | $12,685.00 |
| Education | $87.52 |
| Gift | $59.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $255,403.72 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $185,445.60 | 2019-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Insulet Corporation | $147,386.01 | 2022-2025 | Omnipod, Omnipod |
| Astrazeneca Pharmaceuticals LP | $122,697.11 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $108,294.40 | 2019-2025 | Jardiance |
| Mannkind Corporation | $63,982.83 | 2019-2025 | Afrezza, V-Go |
| Valeritas, INC. | $49,279.90 | 2019 | |
| Lilly USA, LLC | $40,759.16 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Sanofi-Aventis U.S. LLC | $37,509.27 | 2022-2025 | |
| Xeris Pharmaceuticals, INC. | $23,314.95 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Intuity Medical INC | $22,825.27 | 2022-2023 | Pogo Automatic Blood Glucose Monitoring System |
| Cequr Corporation | $21,900.52 | 2022-2025 | Cequr Simplicity |
| Ascendis Pharma Endocrinology INC | $18,496.62 | 2025 | Yorvipath |
| Zealand Pharma US, INC. | $8,740.98 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $6,302.95 | 2022-2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius Kabi USA, LLC | $5,089.97 | 2024 | Stimufend |
| Ascensia Diabetes Care US INC. | $4,214.81 | 2023-2024 | |
| Corcept Therapeutics | $478.71 | 2024-2025 | Korlym |
| Tandem Diabetes Care, INC. | $309.13 | 2020-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Baxter Healthcare | $295.47 | 2019-2024 | Tisseel, Hillrom - Carnation Ambulatory Monitor |
| Genzyme Corporation | $245.00 | 2020 | |
| Medtronic Minimed, INC. | $213.97 | 2019-2020 | |
| Medtronic, INC. | $84.13 | 2022-2025 | Minimed 780g |
| Amneal Pharmaceuticals LLC | $39.87 | 2024 | Unithroid |
| Antares Pharma, INC. | $39.43 | 2025 | Xyosted |
| Amgen INC. | $34.84 | 2024-2025 | Tepezza |
| Beta Bionics, INC. | $31.67 | 2023 | Ilet Bionic Pancreas |
| Sequel Med Tech, LLC | $27.88 | 2025 | Twiist |
| Companion Medical, INC. | $24.03 | 2020 | |
| Alexion Pharmaceuticals, INC. | $23.86 | 2025 | Strensiq |
| Alkermes, INC. | $20.89 | 2025 | Aristada, Lybalvi |
| Abbott Laboratories | $19.61 | 2022 | |
| Tolmar, INC. | $17.89 | 2025 | Jatenzo |
| Abbvie INC. | $16.94 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Martin Sarkar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.